Novel therapies for treatment of resistant and refractory nontuberculous mycobacterial infections in patients with cystic fibrosis

Abstract Respiratory infections caused by non‐tuberculous mycobacteria (NTM) are a major cause of morbidity for patients living with cystic fibrosis (CF), as NTM pulmonary disease (NTM‐PD) is challenging to both diagnose and eradicate. Despite the lengthy courses established regimens recommended Cystic Fibrosis Foundation (CFF) European Society (ECFS) consensus guidelines, only about 50% 60% achieve culture conversion, treatment often complicated antibiotic resistance toxicities. Since publication CFF/ECFS several new or alternative have been described CF who NTM‐PD. These offer options do not clear standard therapies cannot utilize usual due toxicities drug‐drug interactions.